Search

Author/Creator Czibere, A.

1. NEOTALA: an open-label, single-arm, multi-center, phase 2 study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple negative breast cancer (TNBC). (March 2019)

Authors:
Litton, J.; Symmans, F.; Gogineni, K.; Saltzman, M.; Telli, M.L.; Usha, L.; Chakrabarti, J.; Tudor, I.C.; Quek, R.G.W.; Czibere, A.
Journal:
Breast
Issue:
Volume 44(2019)Supplement 1
Page Start:
S73
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3. (23rd June 2022)

Authors:
Lesokhin, A. M.; Arnulf, B.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Tomasson, M. H.; Rodrίguez-Otero, P.; Quach, H.; Raje, N. S.; Iida, S.; Raab, M.-S.; Czibere, A.; Sullivan, S.; Leip, E.; Viqueira, A.; Leleu, X.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
839
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search